TPN171H
Phase 3Small molecule
TPN171H is one of 112 small molecule programs targeting Erectile Dysfunction. It is currently in Phase 3.
3
Indications
14
Total Trials
0
Active Trials
111
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
179 competitors in Pulmonary Arterial Hypertension
#DrugCompanyPhaseTrials
1Gleevec
NovartisPhase 3
Levitra
BayerPhase 3
Reata
BiogenPhase 3
Aurlumyn
BBTG International Inc.
Phase 3
Flolan
Johnson & JohnsonPhase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Inhaled Iloprost
BayerPhase 3
Atrovent
Boehringer IngelheimPhase 3
Actos
TakedaPhase 2
Benadryl
PParkedale
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Erectile Dysfunction4 trials
Pulmonary Arterial Hypertension2 trials
Interaction2 trials
Moderate Hepatic Insufficiency1 trial
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TPN171H. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVigonvita Life Sciences